Details of Disease

General Information of Disease (ID: DISKHX7S)

Disease Name Pancreatic adenocarcinoma
Synonyms PAAD; pancreas adenocarcinoma; adenocarcinoma of the pancreas; adenocarcinoma - pancreas; adenocarcinoma of pancreas; pancreatic adenocarcinoma
Definition A carcinoma that arises from glandular epithelial cells of the pancreas
Disease Hierarchy
DIS3IHTY: Adenocarcinoma
DISJC981: Pancreatic cancer
DISKHX7S: Pancreatic adenocarcinoma
Disease Identifiers
MONDO ID
MONDO_0006047
UMLS CUI
C0281361
MedGen ID
83800
HPO ID
HP:0006725
SNOMED CT ID
700423003

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 4 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Erlotinib DMCMBHA Approved Small molecular drug [1]
Fluorouracil DMUM7HZ Approved Small molecular drug [2]
Gemcitabine DMSE3I7 Approved Small molecular drug [3]
Mitomycin DMH0ZJE Approved Small molecular drug [4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 58 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CCKBR TTVFO0U Limited Genetic Variation [5]
FGFBP1 TTV1YFT Limited Altered Expression [6]
GAST TT4LRVO Limited Biomarker [7]
GEM TTAZF9M Limited Genetic Variation [8]
IAPP TTHN8EM Limited Biomarker [9]
IL1RAP TTWS50K Limited Biomarker [10]
IL1RL1 TT4GZA4 Limited Altered Expression [10]
MUC16 TTC1PS3 Limited Biomarker [11]
PDX1 TT8SGZK Limited Genetic Variation [12]
PSCA TT9T4AV Limited Altered Expression [13]
RRM2 TT1S4LJ Limited Biomarker [14]
SLC29A1 TTLXAKE Limited Biomarker [15]
SSTR2 TTZ6T9E Limited Altered Expression [16]
SLCO4A1 TTV1YIE Disputed Altered Expression [17]
CEACAM6 TTIGH2W moderate Biomarker [18]
FABP1 TTIV96N moderate Biomarker [19]
AGPAT2 TT9AYVR Strong Biomarker [20]
ALPI TTHYMUV Strong Biomarker [21]
ANXA10 TT0NL6U Strong Altered Expression [22]
BRCA2 TTUARD6 Strong Genetic Variation [23]
BTLA TTER58P Strong Biomarker [24]
CBX7 TTBN3HC Strong Altered Expression [25]
CDC7 TTSMTDI Strong Biomarker [26]
CTRC TT3RMNA Strong Genetic Variation [27]
CUBN TT9YLCR Strong Genetic Variation [28]
DCK TTJOCE4 Strong Altered Expression [29]
DPEP1 TTYUENF Strong Biomarker [30]
DYRK1B TTYGQ8A Strong Altered Expression [31]
EPHA4 TTG84D3 Strong Altered Expression [32]
ERBB2 TTR5TV4 Strong Genetic Variation [33]
F11 TTDM4ZU Strong Biomarker [34]
F3 TT38MDJ Strong Altered Expression [35]
FES TTLBY21 Strong Biomarker [36]
HDAC1 TT6R7JZ Strong Altered Expression [37]
HDAC7 TTMUEK1 Strong Altered Expression [38]
HMGA1 TTBA219 Strong Biomarker [39]
JAG2 TTOJY1B Strong Biomarker [40]
LILRB2 TTHC6XU Strong Genetic Variation [41]
LTB4R2 TTVJX54 Strong Altered Expression [42]
MAP2K2 TT8H9GB Strong Genetic Variation [33]
MAP3K1 TTW8TJI Strong Biomarker [43]
MSLN TT4RXME Strong Genetic Variation [44]
MTAP TTDBX7N Strong Genetic Variation [45]
MUC17 TTVO0JU Strong Altered Expression [46]
MVD TTE5J6X Strong Altered Expression [47]
MYCN TT9JBY5 Strong Genetic Variation [33]
NEDD4 TT1QU6G Strong Altered Expression [48]
PRSS1 TT2WR1T Strong Genetic Variation [49]
RXRA TT6PEUO Strong Genetic Variation [33]
SLCO1B3 TTU86P0 Strong Biomarker [50]
EPCAM TTZ8WH4 Definitive Altered Expression [51]
EYA2 TTUY9C6 Definitive Altered Expression [52]
F2R TTL935N Definitive Biomarker [53]
MARK2 TTAJ45Y Definitive Biomarker [53]
RNF43 TTD91BL Definitive Genetic Variation [54]
SLC52A2 TT6TKEN Definitive Biomarker [53]
TRPM7 TTFPVZO Definitive Biomarker [55]
TRPM8 TTXDKTO Definitive Biomarker [56]
------------------------------------------------------------------------------------
⏷ Show the Full List of 58 DTT(s)
This Disease Is Related to 3 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC39A3 DTH08M7 Limited Altered Expression [57]
SLC28A1 DT0EQPW Strong Biomarker [58]
SLC5A8 DTE3TAW Strong Posttranslational Modification [59]
------------------------------------------------------------------------------------
This Disease Is Related to 3 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
UGT1A7 DEZO4N3 Limited Genetic Variation [60]
DCTD DEXL3P2 moderate Biomarker [61]
NAT1 DE7OAB3 Strong Biomarker [62]
------------------------------------------------------------------------------------
This Disease Is Related to 88 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
AHNAK OT6KH1WG Limited Biomarker [63]
CCN5 OTADU8JJ Limited Biomarker [64]
CDX2 OTCG4TSY Limited Biomarker [65]
LGALS4 OTKQCG0H Limited Genetic Variation [66]
LUM OTSRC874 Limited Biomarker [67]
NSD3 OT3677ZG Limited Biomarker [68]
PLPP5 OTHT51D6 Limited Biomarker [68]
SMAGP OT57BZII Limited Biomarker [69]
SPINK1 OTSUVAL2 Limited Genetic Variation [27]
LRP10 OT8490HT moderate Altered Expression [70]
MAPK8IP2 OTDUHLN0 moderate Biomarker [71]
MUC4 OTLT11V1 moderate Altered Expression [58]
RAB38 OTU0NZU0 moderate Altered Expression [72]
SMG1 OTTS3SXE moderate Biomarker [73]
TRIM29 OT2DNESG moderate Biomarker [74]
ATP1A3 OTM8EG6H Strong Biomarker [30]
BRCA1 OT5BN6VH Strong Biomarker [75]
CBX3 OTOP9RLD Strong Biomarker [76]
CCDC34 OTZ3AGSQ Strong Altered Expression [77]
CCDC6 OTXRQDYG Strong Biomarker [78]
CCL1 OT23NON8 Strong Genetic Variation [79]
CCL14 OT8QETQU Strong Altered Expression [80]
CD109 OTDADBM4 Strong Altered Expression [81]
CEACAM4 OT0C7YUD Strong Altered Expression [82]
CELA3B OTGU8BE9 Strong Genetic Variation [83]
CHD5 OTS5EVHH Strong Altered Expression [84]
CPQ OTTNZNLD Strong Biomarker [30]
DOC2A OT5G9V94 Strong Altered Expression [85]
DUOX2 OTU14HCN Strong Altered Expression [86]
FLOT2 OTZ0QR5L Strong Altered Expression [51]
GIPC1 OTXLVCPJ Strong Biomarker [87]
GNAS OTMH8BKJ Strong Genetic Variation [33]
GNMT OT0O2OQO Strong Biomarker [88]
GPC1 OTQKRSSV Strong Biomarker [89]
HOXB7 OTC7WYU8 Strong Biomarker [90]
IFIT3 OTPGHZB9 Strong Biomarker [91]
KDM4D OTN6KAE6 Strong Biomarker [92]
KLF10 OT4F4UGS Strong Altered Expression [93]
LLGL1 OTAIQSXZ Strong Altered Expression [94]
LSP1 OTSPSIFO Strong Biomarker [95]
MAU2 OTALDF8Q Strong Biomarker [96]
MED12 OTQZ4D2X Strong Genetic Variation [33]
MIA2 OTOGTUTU Strong Genetic Variation [97]
MUC3A OTI4XUDY Strong Altered Expression [46]
MUC7 OTSTMP0X Strong Biomarker [98]
NAPSA OT6F8IAL Strong Genetic Variation [99]
NECTIN1 OTTE5ZR6 Strong Biomarker [100]
NECTIN3 OTS8N7MK Strong Biomarker [101]
NELFE OTL4E94L Strong Biomarker [30]
NKX6-2 OT7FI94W Strong Biomarker [102]
NUPR1 OT4FU8C0 Strong Biomarker [103]
PALB2 OT6DNDBG Strong Genetic Variation [104]
PCP2 OT3LUE9M Strong Biomarker [105]
PDHX OTG7O271 Strong Biomarker [106]
PHLPP1 OTIFXW8D Strong Altered Expression [107]
PIWIL1 OT7CRGZ3 Strong Altered Expression [108]
POLE OTFM3MMU Strong Genetic Variation [33]
POLR2D OTW7RZ18 Strong Altered Expression [109]
PTPRT OTV5TXNN Strong Genetic Variation [105]
PTPRU OTHDO0QG Strong Biomarker [105]
QSOX1 OT4ZPK4P Strong Altered Expression [110]
RAB11B OT6GI23M Strong Biomarker [111]
RBL2 OTBQSOE6 Strong Biomarker [112]
RBM39 OTCMPTF9 Strong Altered Expression [80]
RECQL OTPCH3JH Strong Biomarker [113]
RGS19 OTBIELDO Strong Biomarker [114]
RHOC OTOLE1FT Strong Altered Expression [115]
RIOK3 OTZYZVIX Strong Biomarker [116]
RREB1 OT62460U Strong Altered Expression [57]
S100A14 OTVFJJ91 Strong Altered Expression [117]
SARNP OTE0OVK5 Strong Altered Expression [80]
SBF2 OTBB8NO8 Strong Genetic Variation [118]
SCTR OTC80IMR Strong Biomarker [119]
SEL1L OTC0FB7T Strong Altered Expression [120]
SF3B2 OTNW2U4Y Strong Genetic Variation [33]
SLC12A9 OTR7VRAK Strong Altered Expression [121]
SMAD4 OTWQWCKG Strong Genetic Variation [33]
SPAG1 OT29JZKW Strong Biomarker [122]
SPINK7 OTK3VOI3 Strong Genetic Variation [79]
ST3GAL3 OTOORKUE Strong Biomarker [123]
TAS2R38 OTX5MM36 Strong Biomarker [78]
THEM4 OTSIZU8Y Strong Biomarker [124]
THOC1 OTVABJ4Z Strong Biomarker [125]
TJP2 OTQUY6BV Strong Altered Expression [126]
TM9SF2 OTA0C202 Strong Altered Expression [127]
TPD52L2 OTTOG0NK Strong Biomarker [128]
PACC1 OTKBS8CC Definitive Biomarker [129]
STK11 OT1YZSP3 Definitive Biomarker [130]
------------------------------------------------------------------------------------
⏷ Show the Full List of 88 DOT(s)

References

1 Erlotinib FDA Label
2 Fluorouracil FDA Label
3 Gemcitabine FDA Label
4 Mitomycin FDA Label
5 A Common CCK-B Receptor Intronic Variant in Pancreatic Adenocarcinoma in a Hungarian Cohort.Pancreas. 2016 Apr;45(4):541-5. doi: 10.1097/MPA.0000000000000539.
6 Expression of a fibroblast growth factor-binding protein during the development of adenocarcinoma of the pancreas and colon.Cancer Res. 2006 Jan 15;66(2):1191-8. doi: 10.1158/0008-5472.CAN-05-2926.
7 The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas.Cancer Res. 2004 Aug 15;64(16):5624-31. doi: 10.1158/0008-5472.CAN-04-0106.
8 Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.Medicine (Baltimore). 2017 Apr;96(16):e6544. doi: 10.1097/MD.0000000000006544.
9 An unusual presentation of a benign pancreatic lesion containing amyloid.BMJ Case Rep. 2017 Jul 24;2017:bcr2017219861. doi: 10.1136/bcr-2017-219861.
10 Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells.Cytokine. 2012 Nov;60(2):514-21. doi: 10.1016/j.cyto.2012.06.286. Epub 2012 Jul 20.
11 Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma.Pancreatology. 2018 Sep;18(6):671-677. doi: 10.1016/j.pan.2018.05.479. Epub 2018 Jul 7.
12 DNA released from neutrophil extracellular traps (NETs) activates pancreatic stellate cells and enhances pancreatic tumor growth.Oncoimmunology. 2019 Jun 11;8(9):e1605822. doi: 10.1080/2162402X.2019.1605822. eCollection 2019.
13 Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer.Ann Surg Oncol. 2006 Dec;13(12):1645-54. doi: 10.1245/s10434-006-9029-5.
14 RETRACTED: Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer.Surgery. 2004 Aug;136(2):261-9. doi: 10.1016/j.surg.2004.04.029.
15 Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.Oncol Rep. 2007 May;17(5):1201-5.
16 Mechanisms of inhibition of growth of human pancreatic carcinoma implanted in nude mice by somatostatin receptor subtype 2.Pancreas. 2004 Aug;29(2):141-51. doi: 10.1097/00006676-200408000-00009.
17 Organic anion transporting polypeptides expressed in pancreatic cancer may serve as potential diagnostic markers and therapeutic targets for early stage adenocarcinomas.Pharm Res. 2013 Sep;30(9):2260-9. doi: 10.1007/s11095-012-0962-7. Epub 2013 Jan 11.
18 Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness.Oncogene. 2004 Jul 29;23(34):5834-42. doi: 10.1038/sj.onc.1207775.
19 Computational prediction and experimental validation associating FABP-1 and pancreatic adenocarcinoma with diabetes.BMC Gastroenterol. 2011 Jan 20;11:5. doi: 10.1186/1471-230X-11-5.
20 Lysophosphatidic acid acyltransferase beta regulates mTOR signaling. PLoS One. 2013 Oct 31;8(10):e78632.
21 Primers on molecular pathways - cycling toward pancreatic cancer.Pancreatology. 2010;10(1):6-13. doi: 10.1159/000283646. Epub 2010 Mar 19.
22 Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.PLoS One. 2017 Apr 3;12(4):e0175039. doi: 10.1371/journal.pone.0175039. eCollection 2017.
23 Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?.J Surg Oncol. 2019 May;119(6):777-783. doi: 10.1002/jso.25376. Epub 2019 Jan 12.
24 Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma.Oncoimmunology. 2019 Feb 3;8(4):e1561120. doi: 10.1080/2162402X.2018.1561120. eCollection 2019.
25 CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.Oncotarget. 2017 Jan 31;8(5):8010-8021. doi: 10.18632/oncotarget.14037.
26 Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint.Oncotarget. 2016 Apr 5;7(14):18495-507. doi: 10.18632/oncotarget.7611.
27 CFTR, SPINK1, PRSS1, and CTRC mutations are not associated with pancreatic cancer in German patients.Pancreas. 2014 Oct;43(7):1078-82. doi: 10.1097/MPA.0000000000000166.
28 Vitamin D metabolic pathway genes and pancreatic cancer risk.PLoS One. 2015 Mar 23;10(3):e0117574. doi: 10.1371/journal.pone.0117574. eCollection 2015.
29 HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.Expert Rev Anticancer Ther. 2009 Oct;9(10):1439-41. doi: 10.1586/era.09.119.
30 Comparison of robotic vs laparoscopic vs open distal pancreatectomy. A systematic review and network meta-analysis.HPB (Oxford). 2019 Oct;21(10):1268-1276. doi: 10.1016/j.hpb.2019.04.010. Epub 2019 May 9.
31 DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS.Nat Struct Mol Biol. 2010 Jun;17(6):718-25. doi: 10.1038/nsmb.1833. Epub 2010 May 30.
32 Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice.Oncotarget. 2015 Dec 1;6(38):41063-76. doi: 10.18632/oncotarget.5729.
33 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
34 Differential contribution of tissue factor and FactorXII to thrombin generation triggered by breast and pancreatic cancer cells.Int J Oncol. 2017 Dec;51(6):1747-1756. doi: 10.3892/ijo.2017.4172. Epub 2017 Oct 20.
35 Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma.Oncotarget. 2017 Jul 10;8(35):59086-59102. doi: 10.18632/oncotarget.19175. eCollection 2017 Aug 29.
36 DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma.Cancer Genet Cytogenet. 2000 Jan 15;116(2):133-41. doi: 10.1016/s0165-4608(99)00118-1.
37 Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.BMC Gastroenterol. 2015 Oct 26;15:148. doi: 10.1186/s12876-015-0379-y.
38 Further characterization of HDAC and SIRT gene expression patterns in pancreatic cancer and their relation to disease outcome.PLoS One. 2014 Oct 2;9(9):e108520. doi: 10.1371/journal.pone.0108520. eCollection 2014.
39 The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma. Pancreatology. 2012 Jul-Aug;12(4):372-9.
40 MicroRNA-876-3p functions as a tumor suppressor gene and correlates with cell metastasis in pancreatic adenocarcinoma via targeting JAG2.Am J Cancer Res. 2018 Apr 1;8(4):636-649. eCollection 2018.
41 Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer.PLoS One. 2011;6(6):e20687. doi: 10.1371/journal.pone.0020687. Epub 2011 Jun 27.
42 BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation.Br J Cancer. 2008 Oct 7;99(7):1064-73. doi: 10.1038/sj.bjc.6604655. Epub 2008 Sep 9.
43 Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells.J Cancer Res Clin Oncol. 2009 Dec;135(12):1655-63. doi: 10.1007/s00432-009-0612-6. Epub 2009 Jun 10.
44 Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma.Clin Cancer Res. 2020 Feb 15;26(4):828-836. doi: 10.1158/1078-0432.CCR-19-2586. Epub 2019 Dec 2.
45 Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy.Cancer Biol Ther. 2005 Jan;4(1):83-6. doi: 10.4161/cbt.4.1.1380. Epub 2005 Jan 15.
46 Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia.Pancreas. 2003 Apr;26(3):e48-54. doi: 10.1097/00006676-200304000-00022.
47 Expression of IL-6 receptor in pancreatic cancer: involvement in VEGF induction.Anticancer Res. 2002 Nov-Dec;22(6C):4093-100.
48 The E3 ubiquitin ligase NEDD4 is translationally upregulated and facilitates pancreatic cancer.Oncotarget. 2017 Mar 21;8(12):20288-20296. doi: 10.18632/oncotarget.15446.
49 Characterization of novel genetic alterations in salivary gland secretory carcinoma.Mod Pathol. 2020 Apr;33(4):541-550. doi: 10.1038/s41379-019-0427-1. Epub 2019 Dec 10.
50 Characterization of OATP1B3 and OATP2B1 transporter expression in the islet of the adult human pancreas.Histochem Cell Biol. 2017 Oct;148(4):345-357. doi: 10.1007/s00418-017-1580-6. Epub 2017 May 10.
51 Expression of CD44, CD24 and ESA in pancreatic adenocarcinoma cell lines varies with local microenvironment.Hepatobiliary Pancreat Dis Int. 2011 Aug;10(4):428-34. doi: 10.1016/s1499-3872(11)60073-8.
52 Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth.Oncotarget. 2014 May 15;5(9):2575-87. doi: 10.18632/oncotarget.1842.
53 Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion.Cancer Res. 2019 Jul 1;79(13):3417-3430. doi: 10.1158/0008-5472.CAN-18-3206. Epub 2019 May 2.
54 Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma.Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12649-54. doi: 10.1073/pnas.1307218110. Epub 2013 Jul 11.
55 Targeted silencing of TRPM7 ion channel induces replicative senescence and produces enhanced cytotoxicity with gemcitabine in pancreatic adenocarcinoma.Cancer Lett. 2012 May 1;318(1):99-105. doi: 10.1016/j.canlet.2011.12.007. Epub 2011 Dec 11.
56 TRPM8 Ion Channels as Potential Cancer Biomarker and Target in Pancreatic Cancer.Adv Protein Chem Struct Biol. 2016;104:127-155. doi: 10.1016/bs.apcsb.2016.01.001. Epub 2016 Feb 22.
57 The cytotoxic role of RREB1, ZIP3 zinc transporter, and zinc in human pancreatic adenocarcinoma.Cancer Biol Ther. 2014 Oct;15(10):1431-7. doi: 10.4161/cbt.29927. Epub 2014 Jul 22.
58 The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.Oncogene. 2013 Mar 28;32(13):1714-23. doi: 10.1038/onc.2012.179. Epub 2012 May 14.
59 Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer.Pancreas. 2008 May;36(4):e32-9. doi: 10.1097/MPA.0b013e3181630ffe.
60 Polymorphisms of UDP-glucuronosyltransferase 1A7 are not involved in pancreatic diseases.J Med Genet. 2005 Oct;42(10):e62. doi: 10.1136/jmg.2005.032599.
61 Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.Br J Cancer. 2018 Apr;118(8):1084-1088. doi: 10.1038/s41416-018-0005-1. Epub 2018 Mar 9.
62 Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer.Carcinogenesis. 2006 Jan;27(1):103-11. doi: 10.1093/carcin/bgi171. Epub 2005 Jun 29.
63 Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition.J Cancer. 2019 Jun 10;10(16):3860-3870. doi: 10.7150/jca.31291. eCollection 2019.
64 Loss of WISP-2/CCN5 signaling in human pancreatic cancer: a potential mechanism for epithelial-mesenchymal-transition.Cancer Lett. 2007 Aug 28;254(1):63-70. doi: 10.1016/j.canlet.2007.02.012. Epub 2007 Mar 26.
65 CDX2 inhibits pancreatic adenocarcinoma cell proliferation via promoting tumor suppressor miR-615-5p.Tumour Biol. 2016 Jan;37(1):1041-9. doi: 10.1007/s13277-015-3900-6. Epub 2015 Aug 14.
66 Promoter hypermethylation of LGALS4 correlates with poor prognosis in patients with urothelial carcinoma.Oncotarget. 2017 Apr 4;8(14):23787-23802. doi: 10.18632/oncotarget.15865.
67 Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma.Cell Death Differ. 2019 Jan;26(2):382-393. doi: 10.1038/s41418-018-0207-3. Epub 2018 Oct 3.
68 PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung tumors.Am J Pathol. 2013 Nov;183(5):1634-1644. doi: 10.1016/j.ajpath.2013.07.028. Epub 2013 Sep 17.
69 Overexpression of the small transmembrane and glycosylated protein SMAGP supports metastasis formation of a rat pancreatic adenocarcinoma line.Int J Cancer. 2005 Dec 20;117(6):913-22. doi: 10.1002/ijc.21275.
70 Expression of LDL receptor-related proteins (LRPs) in common solid malignancies correlates with patient survival.PLoS One. 2017 Oct 31;12(10):e0186649. doi: 10.1371/journal.pone.0186649. eCollection 2017.
71 A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors.Oncologist. 2019 Jan;24(1):14-e10. doi: 10.1634/theoncologist.2017-0665. Epub 2018 Aug 16.
72 High expression of RAB38 promotes malignant progression of pancreatic cancer.Mol Med Rep. 2019 Feb;19(2):909-918. doi: 10.3892/mmr.2018.9732. Epub 2018 Dec 10.
73 A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene.PLoS Genet. 2019 Aug 30;15(8):e1008344. doi: 10.1371/journal.pgen.1008344. eCollection 2019 Aug.
74 TRIM29 as a novel biomarker in pancreatic adenocarcinoma.Dis Markers. 2014;2014:317817. doi: 10.1155/2014/317817. Epub 2014 Apr 22.
75 Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.Genet Med. 2019 Jan;21(1):213-223. doi: 10.1038/s41436-018-0009-5. Epub 2018 Jul 2.
76 Overexpression of CBX3 in Pancreatic Adenocarcinoma Promotes Cell Cycle Transition-Associated Tumor Progression.Int J Mol Sci. 2018 Jun 14;19(6):1768. doi: 10.3390/ijms19061768.
77 Expression of Coiled-Coil Domain Containing 34 (CCDC34) and its Prognostic Significance in Pancreatic Adenocarcinoma.Med Sci Monit. 2017 Dec 19;23:6012-6018. doi: 10.12659/msm.907951.
78 Cytological evaluation by fine needle aspiration biopsy of incidental focal increased fluorodeoxyglucose uptake in thyroid on positron emission tomography scan.Diagn Cytopathol. 2017 Jun;45(6):501-506. doi: 10.1002/dc.23695. Epub 2017 Mar 6.
79 Short tandem repeat polymorphisms of exon 4 in Kazal-type gene ECRG2 in pancreatic carcinoma and chronic pancreatitis.Anticancer Res. 2007 Jan-Feb;27(1A):69-73.
80 An integrated approach in the discovery and characterization of a novel nuclear protein over-expressed in liver and pancreatic tumors.FEBS Lett. 2001 May 11;496(2-3):109-16. doi: 10.1016/s0014-5793(01)02409-7.
81 Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer.Oncotarget. 2018 Apr 13;9(28):19994-20007. doi: 10.18632/oncotarget.25017. eCollection 2018 Apr 13.
82 The protein core of the NCA-related pancreatic adenocarcinoma-associated antigen (DD9-Ag) is NCA-50.Pancreas. 1993 Mar;8(2):166-70. doi: 10.1097/00006676-199303000-00005.
83 Elastase 3B mutation links to familial pancreatitis with diabetes and pancreatic adenocarcinoma.J Clin Invest. 2019 Aug 1;129(11):4676-4681. doi: 10.1172/JCI129961.
84 Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.Oncogene. 2014 Nov 20;33(47):5450-6. doi: 10.1038/onc.2013.488. Epub 2013 Nov 25.
85 Doc-2/hDab2 expression is up-regulated in primary pancreatic cancer but reduced in metastasis.Lab Invest. 2001 Jun;81(6):863-73. doi: 10.1038/labinvest.3780295.
86 IL-4 and IL-17A Cooperatively Promote Hydrogen Peroxide Production, Oxidative DNA Damage, and Upregulation of Dual Oxidase 2 in Human Colon and Pancreatic Cancer Cells.J Immunol. 2019 Nov 1;203(9):2532-2544. doi: 10.4049/jimmunol.1800469. Epub 2019 Sep 23.
87 Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth.Clin Cancer Res. 2009 Jun 15;15(12):4095-103. doi: 10.1158/1078-0432.CCR-08-2837. Epub 2009 Jun 9.
88 Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma.Cancer Genomics Proteomics. 2015 Jan-Feb;12(1):21-30.
89 Prognostic value of glypican-1 for patients with advanced pancreatic cancer following regional intra-arterial chemotherapy.Oncol Lett. 2018 Jul;16(1):1253-1258. doi: 10.3892/ol.2018.8701. Epub 2018 May 11.
90 HOXB7 promotes invasion and predicts survival in pancreatic adenocarcinoma.Cancer. 2013 Feb 1;119(3):529-39. doi: 10.1002/cncr.27725. Epub 2012 Aug 22.
91 Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease.BMC Cancer. 2017 Mar 29;17(1):229. doi: 10.1186/s12885-017-3186-8.
92 KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma.Anticancer Res. 2018 Apr;38(4):2295-2302. doi: 10.21873/anticanres.12474.
93 Krppel-like factor 10 expression as a prognostic indicator for pancreatic adenocarcinoma.Am J Pathol. 2012 Aug;181(2):423-30. doi: 10.1016/j.ajpath.2012.04.025. Epub 2012 Jun 9.
94 Preservation of HUGL-1 expression as a favourable prognostic factor in pancreatic carcinoma.Anticancer Res. 2012 Aug;32(8):3153-9.
95 Association of breast cancer susceptibility variants with risk of pancreatic cancer.Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3044-8. doi: 10.1158/1055-9965.EPI-09-0306. Epub 2009 Oct 20.
96 Survival and prognostic factors in patients with pancreatic squamous cell carcinoma.Eur J Surg Oncol. 2019 Sep;45(9):1700-1705. doi: 10.1016/j.ejso.2019.05.011. Epub 2019 May 15.
97 A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels.Sci Rep. 2015 Feb 6;5:8109. doi: 10.1038/srep08109.
98 Mucin expression pattern in pancreatic diseases: findings from EUS-guided fine-needle aspiration biopsies.Am J Gastroenterol. 2011 Jul;106(7):1359-63. doi: 10.1038/ajg.2011.22. Epub 2011 Jun 7.
99 KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.Mod Pathol. 2014 Feb;27(2):262-70. doi: 10.1038/modpathol.2013.146. Epub 2013 Jul 26.
100 Nectin expression in pancreatic adenocarcinoma: nectin-3 is associated with a poor prognosis.Surg Today. 2015 Apr;45(4):487-94. doi: 10.1007/s00595-015-1126-2. Epub 2015 Feb 19.
101 Nectin-3 is a new biomarker that mediates the upregulation of MMP2 and MMP9 in ovarian cancer cells.Biomed Pharmacother. 2019 Feb;110:139-144. doi: 10.1016/j.biopha.2018.11.020. Epub 2018 Nov 20.
102 Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.Oncologist. 2018 Jan;23(1):4-e10. doi: 10.1634/theoncologist.2017-0208. Epub 2017 Dec 6.
103 Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma.Cells. 2019 Nov 17;8(11):1453. doi: 10.3390/cells8111453.
104 Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8.
105 Characterization of PCP-2, a novel receptor protein tyrosine phosphatase of the MAM domain family.Oncogene. 1996 Jun 20;12(12):2555-62.
106 PDX-1: demonstration of oncogenic properties in pancreatic cancer.Cancer. 2011 Feb 15;117(4):723-33. doi: 10.1002/cncr.25629. Epub 2010 Sep 30.
107 Protein Kinase C Quality Control by Phosphatase PHLPP1Unveils Loss-of-Function Mechanism in Cancer.Mol Cell. 2019 Apr 18;74(2):378-392.e5. doi: 10.1016/j.molcel.2019.02.018. Epub 2019 Mar 20.
108 The stem cell-associated Hiwi gene in human adenocarcinoma of the pancreas: expression and risk of tumour-related death.Br J Cancer. 2008 Oct 7;99(7):1083-8. doi: 10.1038/sj.bjc.6604653. Epub 2008 Sep 9.
109 Evaluation of insulin-like growth factor (IGF-1) and retinol binding protein (RBP-4) levels in patients with newly diagnosed pancreatic adenocarcinoma (PDAC).Pancreatology. 2017 Jul-Aug;17(4):623-628. doi: 10.1016/j.pan.2017.04.001. Epub 2017 Apr 4.
110 High expression of QSOX1 reduces tumorogenesis, and is associated with a better outcome for breast cancer patients.Breast Cancer Res. 2012 Oct 25;14(5):R136. doi: 10.1186/bcr3341.
111 The 'TRIANGLE Operation' by Laparoscopy: Radical Pancreaticoduodenectomy with Major Vascular Resection for Borderline Resectable Pancreatic Head Cancer.Ann Surg Oncol. 2020 May;27(5):1613-1614. doi: 10.1245/s10434-019-08101-4. Epub 2019 Dec 4.
112 MiR-17-5p enhances pancreatic cancer proliferation by altering cell cycle profiles via disruption of RBL2/E2F4-repressing complexes.Cancer Lett. 2018 Jan 1;412:59-68. doi: 10.1016/j.canlet.2017.09.044. Epub 2017 Oct 4.
113 DNA repair gene polymorphisms and risk of pancreatic cancer.Clin Cancer Res. 2009 Jan 15;15(2):740-6. doi: 10.1158/1078-0432.CCR-08-1607.
114 Expression and regulatory role of GAIP-interacting protein GIPC in pancreatic adenocarcinoma.Cancer Res. 2006 Nov 1;66(21):10264-8. doi: 10.1158/0008-5472.CAN-06-2321.
115 Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1.Mol Cancer. 2005 Jun 21;4(1):21. doi: 10.1186/1476-4598-4-21.
116 Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung.BMC Cancer. 2010 Jun 16;10:295. doi: 10.1186/1471-2407-10-295.
117 Weighted Gene Co-Expression Network Analysis Reveals Six Hub Genes Involved in and Tight Junction Function in Pancreatic Adenocarcinoma and their Potential Use in Prognosis.Genet Test Mol Biomarkers. 2019 Dec;23(12):829-836. doi: 10.1089/gtmb.2019.0122.
118 Genome-wide association study of survival in patients with pancreatic adenocarcinoma.Gut. 2014 Jan;63(1):152-60. doi: 10.1136/gutjnl-2012-303477. Epub 2012 Nov 24.
119 Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma.Cancer Res. 2002 Sep 15;62(18):5223-9.
120 SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo.Oncogene. 2003 Sep 25;22(41):6359-68. doi: 10.1038/sj.onc.1206665.
121 Increased stability of P21(WAF1/CIP1) mRNA is required for ROS/ERK-dependent pancreatic adenocarcinoma cell growth inhibition by pyrrolidine dithiocarbamate.Biochim Biophys Acta. 2006 Sep;1763(9):917-26. doi: 10.1016/j.bbamcr.2006.05.015. Epub 2006 Jun 6.
122 Sperm-associated antigen 1 is expressed early in pancreatic tumorigenesis and promotes motility of cancer cells.Oncogene. 2007 Mar 8;26(11):1533-45. doi: 10.1038/sj.onc.1209961. Epub 2006 Sep 18.
123 alpha2,3-sialyltransferase ST3Gal III modulates pancreatic cancer cell motility and adhesion in vitro and enhances its metastatic potential in vivo.PLoS One. 2010 Sep 1;5(9):e12524. doi: 10.1371/journal.pone.0012524.
124 Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.Int J Cancer. 2009 Aug 15;125(4):942-51. doi: 10.1002/ijc.24424.
125 Combination gene therapy with p53 and Thoc1/p84 is more effective than either single agent in an animal model of human pancreatic adenocarcinoma.Int J Oncol. 2006 Mar;28(3):781-5.
126 Tight junction protein ZO-2 is differentially expressed in normal pancreatic ducts compared to human pancreatic adenocarcinoma.Int J Cancer. 1999 Jul 2;82(1):137-44. doi: 10.1002/(sici)1097-0215(19990702)82:1<137::aid-ijc23>3.0.co;2-f.
127 LINC01232 exerts oncogenic activities in pancreatic adenocarcinoma via regulation of TM9SF2.Cell Death Dis. 2019 Sep 20;10(10):698. doi: 10.1038/s41419-019-1896-3.
128 MicroRNA-217 inhibits cell proliferation, invasion and migration by targeting Tpd52l2 in human pancreatic adenocarcinoma.Oncol Rep. 2017 Dec;38(6):3567-3573. doi: 10.3892/or.2017.6036. Epub 2017 Oct 16.
129 3D-spheroids: What can they tell us about pancreatic ductal adenocarcinoma cell phenotype?.Exp Cell Res. 2017 Aug 15;357(2):299-309. doi: 10.1016/j.yexcr.2017.05.027. Epub 2017 May 29.
130 STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas.Am J Pathol. 2001 Dec;159(6):2017-22. doi: 10.1016/S0002-9440(10)63053-2.